Trial Profile
Planned phase II trial of FG 3019 for the treatment of gemcitabine-refractory pancreatic cancer
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 18 May 2010
Price :
$35
*
At a glance
- Drugs Pamrevlumab (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 17 May 2010 New trial record